Which has better earnings and valuation, VCEL or TGTX?

TG Therapeutics has higher revenue and earnings than Vericel. TG Therapeutics is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Vericel $276.26M 8.22 $16.52M $0.42 105.93 TG Therapeutics $616.29M 13.65 $447.18M $2.86 19.21

Is VCEL or TGTX more profitable?

TG Therapeutics has a net margin of 65.95% compared to Vericel's net margin of 7.35%. TG Therapeutics' return on equity of 88.73% beat Vericel's return on equity. Company Net Margins Return on Equity Return on Assets Vericel 7.35% 6.41% 4.61% TG Therapeutics 65.95% 88.73% 43.44%

Does the media prefer VCEL or TGTX?

In the previous week, Vericel had 4 more articles in the media than TG Therapeutics. MarketBeat recorded 6 mentions for Vericel and 2 mentions for TG Therapeutics. Vericel's average media sentiment score of 1.24 beat TG Therapeutics' score of 1.16 indicating that Vericel is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vericel 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive TG Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings & valuation, VCEL or ABVX?

Vericel has higher revenue and earnings than Abivax. Abivax is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Vericel $276.26M 8.22 $16.52M $0.42 105.93 Abivax N/A N/A -$380.27M -$5.21 N/A

Is VCEL or ABVX more profitable?

Vericel has a net margin of 7.35% compared to Abivax's net margin of 0.00%. Vericel's return on equity of 6.41% beat Abivax's return on equity. Company Net Margins Return on Equity Return on Assets Vericel 7.35% 6.41% 4.61% Abivax N/A -99.02% -70.26%

Does the media favor VCEL or ABVX?

In the previous week, Abivax had 13 more articles in the media than Vericel. MarketBeat recorded 19 mentions for Abivax and 6 mentions for Vericel. Vericel's average media sentiment score of 1.24 beat Abivax's score of 0.95 indicating that Vericel is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vericel 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Abivax 6 Very Positive mention(s) 1 Positive mention(s) 7 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer PRAX or VCEL?

In the previous week, Praxis Precision Medicines had 5 more articles in the media than Vericel. MarketBeat recorded 11 mentions for Praxis Precision Medicines and 6 mentions for Vericel. Vericel's average media sentiment score of 1.24 beat Praxis Precision Medicines' score of 0.70 indicating that Vericel is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Praxis Precision Medicines 4 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Vericel 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation and earnings, IBRX or VCEL?

Vericel has higher revenue and earnings than ImmunityBio. ImmunityBio is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ImmunityBio $113.29M 80.98 -$351.40M -$0.85 N/A Vericel $276.26M 8.22 $16.52M $0.42 105.93

Is IBRX or VCEL more profitable?

Vericel has a net margin of 7.35% compared to ImmunityBio's net margin of -606.15%. Vericel's return on equity of 6.41% beat ImmunityBio's return on equity. Company Net Margins Return on Equity Return on Assets ImmunityBio -606.15% N/A -59.53% Vericel 7.35% 6.41% 4.61%

Does the media refer more to IBRX or VCEL?

In the previous week, ImmunityBio had 3 more articles in the media than Vericel. MarketBeat recorded 9 mentions for ImmunityBio and 6 mentions for Vericel. Vericel's average media sentiment score of 1.24 beat ImmunityBio's score of 0.42 indicating that Vericel is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ImmunityBio 2 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Vericel 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation & earnings, SYRE or VCEL?

Vericel has higher revenue and earnings than Spyre Therapeutics. Spyre Therapeutics is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Spyre Therapeutics $890K 8,772.26 -$155.20M -$2.08 N/A Vericel $276.26M 8.22 $16.52M $0.42 105.93

Does the media prefer SYRE or VCEL?

In the previous week, Spyre Therapeutics had 2 more articles in the media than Vericel. MarketBeat recorded 8 mentions for Spyre Therapeutics and 6 mentions for Vericel. Vericel's average media sentiment score of 1.24 beat Spyre Therapeutics' score of 0.42 indicating that Vericel is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Spyre Therapeutics 2 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Vericel 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Vericel (VCEL) Competitors

$44.49 -0.58 (-1.29%)

Closing price 06/30/2026 04:00 PM Eastern

Extended Trading

$44.51 +0.02 (+0.04%)

As of 06/30/2026 05:58 PM Eastern

Compare

VCEL vs. TGTX, ABVX, PRAX, IBRX, and SYRE

Should you buy Vericel stock or one of its competitors? MarketBeat compares Vericel with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Vericel include TG Therapeutics (TGTX), Abivax (ABVX), Praxis Precision Medicines (PRAX), ImmunityBio (IBRX), and Spyre Therapeutics (SYRE). These companies are all part of the "pharmaceutical products" industry.

How does Vericel compare to TG Therapeutics?

Vericel (NASDAQ:VCEL) and TG Therapeutics (NASDAQ:TGTX) are both mid-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, valuation, analyst recommendations, media sentiment, earnings, risk and institutional ownership.

Vericel presently has a consensus target price of $52.50, suggesting a potential upside of 18.00%. TG Therapeutics has a consensus target price of $58.60, suggesting a potential upside of 6.66%. Given Vericel's higher probable upside, equities analysts clearly believe Vericel is more favorable than TG Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vericel	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
TG Therapeutics	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.75

In the previous week, Vericel had 4 more articles in the media than TG Therapeutics. MarketBeat recorded 6 mentions for Vericel and 2 mentions for TG Therapeutics. Vericel's average media sentiment score of 1.24 beat TG Therapeutics' score of 1.16 indicating that Vericel is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vericel	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
TG Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Vericel has a beta of 1.12, indicating that its share price is 12% more volatile than the broader market. Comparatively, TG Therapeutics has a beta of 1.68, indicating that its share price is 68% more volatile than the broader market.

TG Therapeutics has a net margin of 65.95% compared to Vericel's net margin of 7.35%. TG Therapeutics' return on equity of 88.73% beat Vericel's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vericel	7.35%	6.41%	4.61%
TG Therapeutics	65.95%	88.73%	43.44%

TG Therapeutics has higher revenue and earnings than Vericel. TG Therapeutics is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vericel	$276.26M	8.22	$16.52M	$0.42	105.93
TG Therapeutics	$616.29M	13.65	$447.18M	$2.86	19.21

58.6% of TG Therapeutics shares are held by institutional investors. 7.6% of Vericel shares are held by company insiders. Comparatively, 8.9% of TG Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

TG Therapeutics beats Vericel on 12 of the 16 factors compared between the two stocks.

How does Vericel compare to Abivax?

Vericel (NASDAQ:VCEL) and Abivax (NASDAQ:ABVX) are both mid-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, risk, valuation, analyst recommendations, dividends, earnings and profitability.

Vericel currently has a consensus price target of $52.50, indicating a potential upside of 18.00%. Abivax has a consensus price target of $144.46, indicating a potential upside of 8.37%. Given Vericel's higher probable upside, equities research analysts clearly believe Vericel is more favorable than Abivax.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vericel	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Abivax	1 Sell rating(s)	1 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.81

Vericel has a beta of 1.12, indicating that its share price is 12% more volatile than the broader market. Comparatively, Abivax has a beta of 0.69, indicating that its share price is 31% less volatile than the broader market.

In the previous week, Abivax had 13 more articles in the media than Vericel. MarketBeat recorded 19 mentions for Abivax and 6 mentions for Vericel. Vericel's average media sentiment score of 1.24 beat Abivax's score of 0.95 indicating that Vericel is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vericel	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Abivax	6 Very Positive mention(s)	1 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

47.9% of Abivax shares are held by institutional investors. 7.6% of Vericel shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Vericel has a net margin of 7.35% compared to Abivax's net margin of 0.00%. Vericel's return on equity of 6.41% beat Abivax's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vericel	7.35%	6.41%	4.61%
Abivax	N/A	-99.02%	-70.26%

Vericel has higher revenue and earnings than Abivax. Abivax is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vericel	$276.26M	8.22	$16.52M	$0.42	105.93
Abivax	N/A	N/A	-$380.27M	-$5.21	N/A

Summary

Vericel beats Abivax on 11 of the 15 factors compared between the two stocks.

How does Vericel compare to Praxis Precision Medicines?

Praxis Precision Medicines (NASDAQ:PRAX) and Vericel (NASDAQ:VCEL) are both mid-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, media sentiment, dividends, valuation, risk, institutional ownership, analyst recommendations and earnings.

Vericel has a net margin of 7.35% compared to Praxis Precision Medicines' net margin of 0.00%. Vericel's return on equity of 6.41% beat Praxis Precision Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Praxis Precision Medicines	N/A	-43.02%	-40.22%
Vericel	7.35%	6.41%	4.61%

Praxis Precision Medicines has a beta of 2.71, meaning that its stock price is 171% more volatile than the broader market. Comparatively, Vericel has a beta of 1.12, meaning that its stock price is 12% more volatile than the broader market.

Praxis Precision Medicines currently has a consensus target price of $569.63, suggesting a potential upside of 70.15%. Vericel has a consensus target price of $52.50, suggesting a potential upside of 18.00%. Given Praxis Precision Medicines' stronger consensus rating and higher probable upside, equities research analysts plainly believe Praxis Precision Medicines is more favorable than Vericel.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Praxis Precision Medicines	2 Sell rating(s)	1 Hold rating(s)	14 Buy rating(s)	4 Strong Buy rating(s)	2.95
Vericel	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

67.8% of Praxis Precision Medicines shares are held by institutional investors. 3.0% of Praxis Precision Medicines shares are held by company insiders. Comparatively, 7.6% of Vericel shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Vericel has higher revenue and earnings than Praxis Precision Medicines. Praxis Precision Medicines is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Praxis Precision Medicines	$8.55M	1,091.69	-$303.27M	-$13.37	N/A
Vericel	$276.26M	8.22	$16.52M	$0.42	105.93

In the previous week, Praxis Precision Medicines had 5 more articles in the media than Vericel. MarketBeat recorded 11 mentions for Praxis Precision Medicines and 6 mentions for Vericel. Vericel's average media sentiment score of 1.24 beat Praxis Precision Medicines' score of 0.70 indicating that Vericel is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Praxis Precision Medicines	4 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Vericel	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Vericel beats Praxis Precision Medicines on 9 of the 17 factors compared between the two stocks.

How does Vericel compare to ImmunityBio?

ImmunityBio (NASDAQ:IBRX) and Vericel (NASDAQ:VCEL) are both mid-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, profitability, valuation, institutional ownership, dividends, risk and earnings.

ImmunityBio has a beta of 0.03, suggesting that its stock price is 97% less volatile than the broader market. Comparatively, Vericel has a beta of 1.12, suggesting that its stock price is 12% more volatile than the broader market.

ImmunityBio currently has a consensus target price of $14.20, suggesting a potential upside of 62.10%. Vericel has a consensus target price of $52.50, suggesting a potential upside of 18.00%. Given ImmunityBio's stronger consensus rating and higher probable upside, equities analysts clearly believe ImmunityBio is more favorable than Vericel.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ImmunityBio	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Vericel	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

8.6% of ImmunityBio shares are owned by institutional investors. 66.1% of ImmunityBio shares are owned by insiders. Comparatively, 7.6% of Vericel shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, ImmunityBio had 3 more articles in the media than Vericel. MarketBeat recorded 9 mentions for ImmunityBio and 6 mentions for Vericel. Vericel's average media sentiment score of 1.24 beat ImmunityBio's score of 0.42 indicating that Vericel is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ImmunityBio	2 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Vericel	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Vericel has higher revenue and earnings than ImmunityBio. ImmunityBio is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ImmunityBio	$113.29M	80.98	-$351.40M	-$0.85	N/A
Vericel	$276.26M	8.22	$16.52M	$0.42	105.93

Vericel has a net margin of 7.35% compared to ImmunityBio's net margin of -606.15%. Vericel's return on equity of 6.41% beat ImmunityBio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ImmunityBio	-606.15%	N/A	-59.53%
Vericel	7.35%	6.41%	4.61%

Summary

Vericel beats ImmunityBio on 9 of the 16 factors compared between the two stocks.

How does Vericel compare to Spyre Therapeutics?

Spyre Therapeutics (NASDAQ:SYRE) and Vericel (NASDAQ:VCEL) are both mid-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, risk, valuation, profitability, earnings, institutional ownership, dividends and media sentiment.

Spyre Therapeutics has a beta of 3.05, meaning that its stock price is 205% more volatile than the broader market. Comparatively, Vericel has a beta of 1.12, meaning that its stock price is 12% more volatile than the broader market.

Vericel has higher revenue and earnings than Spyre Therapeutics. Spyre Therapeutics is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spyre Therapeutics	$890K	8,772.26	-$155.20M	-$2.08	N/A
Vericel	$276.26M	8.22	$16.52M	$0.42	105.93

In the previous week, Spyre Therapeutics had 2 more articles in the media than Vericel. MarketBeat recorded 8 mentions for Spyre Therapeutics and 6 mentions for Vericel. Vericel's average media sentiment score of 1.24 beat Spyre Therapeutics' score of 0.42 indicating that Vericel is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Spyre Therapeutics	2 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Vericel	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Spyre Therapeutics currently has a consensus target price of $95.83, suggesting a potential upside of 7.94%. Vericel has a consensus target price of $52.50, suggesting a potential upside of 18.00%. Given Vericel's higher probable upside, analysts plainly believe Vericel is more favorable than Spyre Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spyre Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00
Vericel	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

80.4% of Spyre Therapeutics shares are owned by institutional investors. 15.7% of Spyre Therapeutics shares are owned by company insiders. Comparatively, 7.6% of Vericel shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Vericel has a net margin of 7.35% compared to Spyre Therapeutics' net margin of 0.00%. Vericel's return on equity of 6.41% beat Spyre Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Spyre Therapeutics	N/A	-42.88%	-27.76%
Vericel	7.35%	6.41%	4.61%

Summary

Vericel beats Spyre Therapeutics on 9 of the 17 factors compared between the two stocks.

Get Vericel News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VCEL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VCEL vs. The Competition

Export

Metric	Vericel	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$2.30B	$3.66B	$7.07B	$12.45B
Dividend Yield	N/A	2.20%	2.66%	6.16%
P/E Ratio	105.93	20.90	27.51	24.87
Price / Sales	8.22	341.80	540.69	102.84
Price / Cash	81.13	143.77	48.53	58.59
Price / Book	6.35	8.75	11.01	6.54
Net Income	$16.52M	$23.81M	$3.57B	$336.70M
7 Day Performance	6.72%	3.60%	2.31%	2.88%
1 Month Performance	35.56%	3.72%	1.38%	0.64%
1 Year Performance	6.95%	68.80%	36.70%	31.34%

Vericel Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VCEL Vericel	3.3725 of 5 stars	$44.49 -1.3%	$52.50 +18.0%	+4.6%	$2.30B	$276.26M	105.93	300	Insider Trade
TGTX TG Therapeutics	3.1137 of 5 stars	$54.40 +2.2%	$58.60 +7.7%	+52.7%	$8.15B	$700.35M	19.02	290	Positive News
ABVX Abivax	1.9624 of 5 stars	$101.66 +2.5%	$130.08 +28.0%	+1,642.5%	$7.91B	N/A	N/A	61	Trending News Analyst Forecast Gap Up
PRAX Praxis Precision Medicines	3.5414 of 5 stars	$303.39 +7.5%	$566.21 +86.6%	+696.2%	$7.87B	$8.55M	N/A	110	Analyst Forecast Gap Down
IBRX ImmunityBio	2.4901 of 5 stars	$7.22 -1.9%	$14.20 +96.7%	+231.8%	$7.71B	$113.29M	N/A	590	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VCEL) was last updated on 7/1/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Vericel (VCEL) Competitors

VCEL vs. TGTX, ABVX, PRAX, IBRX, and SYRE

How does Vericel compare to TG Therapeutics?

Summary

How does Vericel compare to Abivax?

Summary

How does Vericel compare to Praxis Precision Medicines?

Summary

How does Vericel compare to ImmunityBio?

Summary

How does Vericel compare to Spyre Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VCEL vs. The Competition

Vericel Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Vericel (VCEL) Competitors

VCEL vs. TGTX, ABVX, PRAX, IBRX, and SYRE

How does Vericel compare to TG Therapeutics?

Do analysts recommend VCEL or TGTX?

Does the media prefer VCEL or TGTX?

Which has more risk & volatility, VCEL or TGTX?

Is VCEL or TGTX more profitable?

Which has better earnings and valuation, VCEL or TGTX?

Do institutionals and insiders have more ownership in VCEL or TGTX?

Summary

How does Vericel compare to Abivax?

Do analysts rate VCEL or ABVX?

Which has more risk & volatility, VCEL or ABVX?

Does the media favor VCEL or ABVX?

Do insiders & institutionals have more ownership in VCEL or ABVX?

Is VCEL or ABVX more profitable?

Which has preferable earnings & valuation, VCEL or ABVX?

Summary

How does Vericel compare to Praxis Precision Medicines?

Is PRAX or VCEL more profitable?

Which has more risk & volatility, PRAX or VCEL?

Do analysts rate PRAX or VCEL?

Do institutionals and insiders have more ownership in PRAX or VCEL?

Which has stronger earnings & valuation, PRAX or VCEL?

Does the media prefer PRAX or VCEL?

Summary

How does Vericel compare to ImmunityBio?

Which has more risk and volatility, IBRX or VCEL?

Do analysts recommend IBRX or VCEL?

Do institutionals & insiders hold more shares of IBRX or VCEL?

Does the media refer more to IBRX or VCEL?

Which has stronger valuation and earnings, IBRX or VCEL?

Is IBRX or VCEL more profitable?

Summary

How does Vericel compare to Spyre Therapeutics?

Which has more risk and volatility, SYRE or VCEL?

Which has preferable valuation & earnings, SYRE or VCEL?

Does the media prefer SYRE or VCEL?

Do analysts rate SYRE or VCEL?

Do insiders and institutionals hold more shares of SYRE or VCEL?

Is SYRE or VCEL more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VCEL vs. The Competition

Vericel Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools